255 related articles for article (PubMed ID: 30276344)
1. Pathology of Calcineurin and Mammalian Target of Rapamycin Inhibitors in Kidney Transplantation.
Leal R; Tsapepas D; Crew RJ; Dube GK; Ratner L; Batal I
Kidney Int Rep; 2018 Mar; 3(2):281-290. PubMed ID: 30276344
[TBL] [Abstract][Full Text] [Related]
2. Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: a viable option?
Höcker B; Tönshoff B
Paediatr Drugs; 2011 Feb; 13(1):49-69. PubMed ID: 21162600
[TBL] [Abstract][Full Text] [Related]
3. Costimulatory Blockade and Use of Mammalian Target of Rapamycin Inhibitors: Avoiding Injury Part 1.
Augustine J; Hricik DE
Adv Chronic Kidney Dis; 2016 Sep; 23(5):301-305. PubMed ID: 27742384
[TBL] [Abstract][Full Text] [Related]
4. Conversion of calcineurin inhibitors with mammalian target of rapamycin inhibitors after kidney transplant.
Nikoueinejad H; Soleimani A; Mirshafiey A; Amirzargar A; Sarrafnejad A; Kamkar I; Einollahi B
Exp Clin Transplant; 2013 Feb; 11(1):12-6. PubMed ID: 23387537
[TBL] [Abstract][Full Text] [Related]
5. Systematic Review on Role of Mammalian Target of Rapamycin Inhibitors as an Alternative to Calcineurin Inhibitors in Renal Transplant: Challenges and Window to Excel.
Kumar J; Bridson JM; Sharma A; Halawa A
Exp Clin Transplant; 2017 Jun; 15(3):241-252. PubMed ID: 27915965
[TBL] [Abstract][Full Text] [Related]
6. The future role of target of rapamycin inhibitors in renal transplantation.
Schwarz C; Oberbauer R
Curr Opin Urol; 2002 Mar; 12(2):109-13. PubMed ID: 11859256
[TBL] [Abstract][Full Text] [Related]
7. Mammalian Target of Rapamycin Inhibitors and Clinical Outcomes in Adult Kidney Transplant Recipients.
Badve SV; Pascoe EM; Burke M; Clayton PA; Campbell SB; Hawley CM; Lim WH; McDonald SP; Wong G; Johnson DW
Clin J Am Soc Nephrol; 2016 Oct; 11(10):1845-1855. PubMed ID: 27445164
[TBL] [Abstract][Full Text] [Related]
8. Steroid and calcineurin inhibitor-sparing protocols in kidney transplantation.
Helal I; Chan L
Transplant Proc; 2011 Mar; 43(2):472-7. PubMed ID: 21440737
[TBL] [Abstract][Full Text] [Related]
9. Chronic allograft dysfunction: can we use mammalian target of rapamycin inhibitors to replace calcineurin inhibitors to preserve graft function?
Wali RK; Weir MR
Curr Opin Organ Transplant; 2008 Dec; 13(6):614-21. PubMed ID: 19060552
[TBL] [Abstract][Full Text] [Related]
10. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
Tönshoff B; Höcker B
Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
[TBL] [Abstract][Full Text] [Related]
11. Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients.
Karpe KM; Talaulikar GS; Walters GD
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD006750. PubMed ID: 28730648
[TBL] [Abstract][Full Text] [Related]
12. A Randomized 2x2 Factorial Clinical Trial of Renal Transplantation: Steroid-Free Maintenance Immunosuppression with Calcineurin Inhibitor Withdrawal after Six Months Associates with Improved Renal Function and Reduced Chronic Histopathology.
Stevens RB; Foster KW; Miles CD; Kalil AC; Florescu DF; Sandoz JP; Rigley TH; Malik T; Wrenshall LE
PLoS One; 2015; 10(10):e0139247. PubMed ID: 26465152
[TBL] [Abstract][Full Text] [Related]
13. An update on chemical pharmacotherapy options for the prevention of kidney transplant rejection with a focus on costimulation blockade.
Kälble F; Schaier M; Schäfer S; Süsal C; Zeier M; Sommerer C; Morath C
Expert Opin Pharmacother; 2017 Jun; 18(8):799-807. PubMed ID: 28460546
[TBL] [Abstract][Full Text] [Related]
14. Abatacept as rescue immunosuppression after calcineurin inhibitor treatment failure in renal transplantation.
Badell IR; Karadkhele GM; Vasanth P; Farris AB; Robertson JM; Larsen CP
Am J Transplant; 2019 Aug; 19(8):2342-2349. PubMed ID: 30768841
[TBL] [Abstract][Full Text] [Related]
15. Calcineurin and mTOR inhibitors in kidney transplantation: integrative metamodeling on transplant survival and kidney function.
Khalid H; Fareed MM; Dandekar T; Shityakov S
Int Urol Nephrol; 2024 Apr; 56(4):1403-1414. PubMed ID: 37751051
[TBL] [Abstract][Full Text] [Related]
16. Long-Term Immunosuppression Management: Opportunities and Uncertainties.
Wojciechowski D; Wiseman A
Clin J Am Soc Nephrol; 2021 Aug; 16(8):1264-1271. PubMed ID: 33853841
[TBL] [Abstract][Full Text] [Related]
17. Use of belatacept in kidney transplantation: what's new?
Yakubu I; Moinuddin I; Gupta G
Curr Opin Organ Transplant; 2023 Feb; 28(1):36-45. PubMed ID: 36326538
[TBL] [Abstract][Full Text] [Related]
18. Immunosuppression Minimization and Avoidance Protocols: When Less Is Not More.
Prashar R; Venkat KK
Adv Chronic Kidney Dis; 2016 Sep; 23(5):295-300. PubMed ID: 27742383
[TBL] [Abstract][Full Text] [Related]
19. Oral Preconditioning of Donors After Brain Death With Calcineurin Inhibitors vs. Inhibitors of Mammalian Target for Rapamycin in Pig Kidney Transplantation.
Abbasi Dezfouli S; Nikdad M; Ghamarnejad O; Khajeh E; Arefidoust A; Mohammadi S; Majlesara A; Sabagh M; Gharabaghi N; Kentar M; Younsi A; Eckert C; Poth T; Golriz M; Mehrabi A; Nickkholgh A
Front Immunol; 2020; 11():1222. PubMed ID: 32625210
[No Abstract] [Full Text] [Related]
20. Calcineurin inhibitor-sparing regimens based on mycophenolic acid after kidney transplantation.
Kamar N; Del Bello A; Belliere J; Rostaing L
Transpl Int; 2015 Aug; 28(8):928-37. PubMed ID: 25557802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
